GZ/SAR402671

DRUG2 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Fabry Disease

Phase 2

Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease

CompletedNCT02228460

Genzyme, a Sanofi CompanyFabry Disease

Start: 2014-11-30End: 2016-09-30Updated: 2019-12-17

Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease

CompletedNCT02489344

Genzyme, a Sanofi CompanyFabry Disease

Start: 2015-07-07End: 2018-11-20Updated: 2021-03-23

Related Papers

Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study

Molecular Genetics and Metabolism2022-11-0846 citations

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects

Orphanet Journal of Rare Diseases2020-10-276 citations

MO035HISTORICAL CONTROL ANALYSIS DEMONSTRATES SUPERIOR REDUCTION OF PLASMA GLOBOTRIAOSYLCERAMIDE BY VENGLUSTAT COMPARED WITH PLACEBO OR AGALSIDASE BETA IN CLASSIC FABRY DISEASE PATIENTS

Nephrology Dialysis Transplantation2020-06-011 citations

P0062GLUCOSYLCERAMIDE SYNTHASE INHIBITION WITH VENGLUSTAT IN CLASSIC FABRY DISEASE PATIENTS LEADS TO PROGRESSIVE REDUCTION OF ENDOTHELIAL CELL GLOBOTRIAOSYLCERAMIDE INCLUSION VOLUME

Nephrology Dialysis Transplantation2020-06-011 citations